Summary
Definition
History and exam
Key diagnostic factors
- hypertension
- tachycardia
- chest pain
- mydriasis
- diaphoresis
- tremulousness
- agitation (mild to severe)
- mood changes (e.g., irritability, euphoria, dysphoria, paranoia)
- suicide ideation
Other diagnostic factors
- anxiety (panic state: mild to severe)
- drug-induced formication
- previous hospitalization for medically supervised withdrawal
- heat-related injuries (e.g., blisters, sores, and cuts on the mouth) or burns on the thumbs
- nasal septum ulceration, perforation
- focal neurologic abnormalities
- seizure activity
- loss of consciousness/altered consciousness
- skin lesions (e.g., puncture marks, infections, erosions, necrosis)
- dyspnea
Risk factors
- adverse childhood events
- history of polysubstance use
- family history of substance use disorders
- history of mental health disorder
- early initiation of substance use
- male sex
Diagnostic tests
1st tests to order
- urine toxicology ± gas chromatography/mass spectrometry testing
- ECG
- cardiac enzymes
Tests to consider
- chest x-ray
- CT head
- electroencephalogram
- comprehensive blood panel
- hepatitis serology
- HIV serology
Treatment algorithm
acute intoxication
nonpregnant adults and adolescents
pregnant
sustained remission
treatment resistant
Contributors
Authors
Joao P. De Aquino, MD
Assistant Professor of Psychiatry
Pain and Addiction Interaction Neuroscience (PAIN) Lab
Yale University School of Medicine
New Haven
CT
Disclosures
JPD is supported by the grants from the National Institute on Drug Abuse (NIDA). JPD has also been supported in this study by Jazz Pharmaceuticals and Ananda Scientific, specifically through medication provisions. JPD has been a compensated consultant for Boehringer Ingelheim.
Gabriel P. A. Costa, MD
Postdoctoral Associate
Pain and Addiction Interaction Neuroscience (PAIN) Lab
Yale University School of Medicine
New Haven
CT
Disclosures
GPAC declares that he has no competing interests.
Kim Wolff, MBE, PhD
Professor of Analytical, Forensic, and Addiction Science, Director, King’s Forensics
Faculty Life Science and Medicine
King’s College London
London
UK
Disclosures
KW declares that she has no competing interests.
Acknowledgements
Professor Kim Wolff would like to gratefully acknowledge Dr Steven B. Karch, the previous contributor to this topic.
Disclosures
SBK is an author of a number of references cited in this topic. SBK gives expert testimony and receives royalties from a textbook that he authored.
Peer reviewers
Andrew J. Saxon, MD
Professor
Department of Psychiatry and Behavioral Sciences
University of Washington School of Medicine
Seattle
WA
Divulgaciones
AS declares that he receives royalties from UpToDate, Inc.
Adam Bisaga, MD
Professor
Clinical Psychiatry
Columbia University College of Physicians and Surgeons
New York City
NY
Divulgaciones
AB declares that his research team and institution received funding and medication donations from Alkermes.
Christos Kouimtsidis, MBBS, MSc, MRCPsych, PhD
Consultant Psychiatrist and Honorary Senior Lecturer
Addictions, Alcohol Research
Institute of Psychiatry
King's College London
London
UK
Divulgaciones
CK declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edition, text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.
Clinical Guideline Committee (CGC) Members, ASAM Team, AAAP Team, et al. The ASAM/AAAP clinical practice guideline on the management of stimulant use disorder. J Addict Med. 2024 May-Jun 01;18(1s suppl 1):1-56.Texto completo Resumen
Department of Health and Social Care. Drug misuse and dependence: UK guidelines on clinical management. Dec 2017 [internet publication].Texto completo
World Health Organization. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Nov 2014 [internet publication].Texto completo
National Institute for Health and Care Excellence. Drug misuse in over 16s: psychosocial interventions. Jul 2007 [internet publication].Texto completo
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Thyrotoxicosis
- Amphetamine and methamphetamine use disorder
- Mood disorder
Más DiferencialesGuías de práctica clínica
- Assessment and treatment of adolescents and young adults with substance use disorders and problematic substance use (excluding tobacco)
- Engagement and retention of nonabstinent patients in substance use treatment
Más Guías de práctica clínicaFolletos para el paciente
Cocaine use disorder
Más Folletos para el pacienteInicie sesión o suscríbase para acceder a todo el BMJ Best Practice
El uso de este contenido está sujeto a nuestra cláusula de exención de responsabilidad